InNexus Biotechnology Inc. Expands Team to Focus on Licensing and Partnering
Published: Mar 16, 2011
CHANDLER, Ariz.--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX:IXS.V) (www.ixsbio.com), a leading drug development company commercializing the next generation of antibodies based on its proprietary DXL™ and Transmab™ technologies, today announced the appointment of Jonathan Drutz as Business Development Director. Drutz will lead all licensing, business development and partnering initiatives and programs for InNexus’ DXL™ and Transmab™ antibody technologies.